AI-Powered Fast and Cost-Effective Antibody De Novo Design and Affinity Maturation Service Unveiled

Uncategorized

Revolutionary AI Technology Transforms Antibody Development and Optimization Ainnocence, a leading AI innovator in biotechnology launched a groundbreaking AI-enabled platform for antibody affinity maturation and de novo design. This powerful animal free platform, driven by Ainnocence’s proprietary SentinusAI® protein generative AI engine, is set to revolutionize the field of antibody discovery and optimization by replacing tradition…

Details

BioBuzz with Sino | Episode 1: ChatGPT in Biotech | Dr. Lurong Pan

News, Uncategorised, Uncategorized

Bringing together scientists and experts, Sino Biological’s podcast presents information on trending topics in biotech with high-profile people from the industry, and what we can look forward to seeing with this technology. Dr. Lurong Pan, the founder and CEO of Ainnocence, joins us to discuss ChatGPT, the general-purpose AI chatbot prototype that the internet is…

Details

How AI That Powers Chatbots and Search Queries Could Discover New Drugs

News

Natural language processing algorithms like the ones used in Google searches and OpenAI’s ChatGPT promise to slash the time required to bring medications to market Original Article: https://www.wsj.com/articles/how-ai-that-powers-chatbots-and-search-queries-could-discover-new-drugs-11670428795?mod=foesummaries In their search for new disease-fighting medicines, drug makers have long employed a laborious trial-and-error process to identify the right compounds. But what if artificial intelligence could…

Details

Ainnocence and Sino Biological Partner to Offer Next-Generation CRO Antibody Development Services

News

Beijing, China – March 22, 2022 – Ainnocence, Inc. of San Jose, California, is pleased to announce a CRO services partnership with Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services. Under the terms of this partnership, Sino…

Details

Ainnocence Launches Self-Evolving, Multi-Objective AI Drug Discovery Platform

News

SAN DIEGO, California., June 13, 2022 /PRNewswire/ — Ainnocence, a global biotech startup on a mission to accelerate drug discovery using a fast, self-evolving AI drug design platform, launched today at the 2022 BIO International Convention (booth 4001). Founded by a versatile team of biomedical scientists and computer scientists, Ainnocence provides small- and large-molecule design…

Details